Analyst Reco. NextCure, Inc.

Equities

NXTC

US65343E1082

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
1.53 ^USD	+2.68%		+13.33%	+34.21%

May. 02	NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 08	NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Initiates NextCure With Buy Rating, $7 Price Target	23-08-08	MT
BTIG Lowers NextCure's Price Target to $8 From $27, Maintains Buy Rating	22-11-04	MT
Needham Lowers NextCure's Price Target to $6 From $12, Maintains Buy Rating	22-11-04	MT
Roth Capital Lowers NextCure's Price Target to $4 From $6, Maintains Neutral Rating	22-11-04	MT
Ladenburg Downgrades NextCure to Neutral From Buy	22-11-04	MT
Piper Sandler Adjusts Price Target on NextCure to $6 From $13, Maintains Overweight Rating	22-11-04	MT
Truist Securities Adjusts NextCure's Price Target to $15 From $19, Reiterates Buy Rating	22-08-23	MT
Piper Sandler Lowers NextCure's Price Target to $13 From $21, Maintains Overweight Rating	22-05-23	MT
Ladenburg Thalmann Initiates NextCure at Buy With $16 Price Target	22-03-01	MT
Needham Adjusts Price Target on NextCure to $14 from $30, Keeps Buy Rating	21-11-05	MT
NEXTCURE : Piper Sandler Adjusts NextCure's Price Target to $21 From $26, Maintains Overweight Rating	21-08-09	MT
NEXTCURE : Truist Securities Upgrades NextCure to Buy From Hold; Price Target is $19	21-03-05	MT
NEXTCURE : BofA Securities Downgrades NextCure to Underperform From Neutral, Adjusts Price Target to $10 From $13	21-01-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer